S_mary }The effect of the polyunsaturated fatty acids (PUFAs) linoleic acid (LA) and arachidonic acid (AA) on the growth of two murine colon adenocarcinoma cell lines (MAC26 and MAC13) has been determined both in vitro and in vivo. When the serum concentration in the medium became growth limiting, low concentrations (18-33 pM) of both PUFAs were growth stimulatory to both cell lines, while higher concentrations were growth inhibitory. Growth stimulation by AA in both cell lines, and by LA in MAC13, was effectively inhibited by both the cyclo-oxygenase and lipoxygenase inhibitor indomethacin, and the lipoxygenase inhibitor BWA4C in a dose-dependent manner. The most effective inhibition was exerted by BWA4C, suggesting metabolism of both PUFAs through the lipoxygenase pathway for growth stimulation. In vivo studies using the MAC26 tumour showed a significant stimulation of tumour growth when LA was administered orally at concentrations higher than 0. Ci mmol-') were purchased from Amersham International (Amersham, UK). LA (99%) and AA (99%) were purchased as the free acids from Sigma (Poole, UK). RPMI-1640 tissue culture medium and fetal calf serum were purchased from Gibco (Paisley, UK). Fatty acids were complexed to sterile bovine serum albumin (fatty acid free) in water on an equal weight basis. The acid was neutralised with equimolar sodium bicarbonate and sonicated for 5 min to form micelles. Indomethacin was purchased from Sigma (Dorset, UK). BWA4C was kindly donated by L. Garland, Wellcome Research Laboratories, Kent, UK. The fatty acid composition of the rat and mouse breeding diet and arachis oil was determined by gas-liquid chromatographic (GIC) analysis of the fatty acids as the methyl esters as previously described (Hudson et al., 1993) and is given in Table I .
, breast (Rogers & Wetsel, 1981) and pancreatic cancer (Roebuck et al., 1985) induced by chemical carcinogens. In addition cis, cis-linoleic acid has been shown to promote the growth of transplantable mouse and rat mammary carcinomas (Hillyard & Abraham, 1979) , suggesting that diet may be an important factor in tumour progression for patients with pre-existing cancer.
Although there are no definitive data to support the role of PUFAs in human cancer, there are alterations of the tumour and plasma concentration of some n-6 PUFAs which support this hypothesis. Thus a significant reduction in the concentration of arachidonic (AA) is observed in malignant prostatic tissue compared with benign (Chaudry et al., 1991) and may be due to an increased metabolism. Lower levels of LA as a percentage of total fatty acids have also been observed in plasma phospholipids and cholesterol esters and in red blood cell phospholipids in cancer patients with weight loss (Mosconi et al., 1989) . In contrast, the AA concentration was found to be increased in human colorectal cancer compared with the unaffected mucosa (Neoptolemos et al., 1991 Ci mmol-') were purchased from Amersham International (Amersham, UK). LA (99%) and AA (99%) were purchased as the free acids from Sigma (Poole, UK). RPMI-1640 tissue culture medium and fetal calf serum were purchased from Gibco (Paisley, UK). Fatty acids were complexed to sterile bovine serum albumin (fatty acid free) in water on an equal weight basis. The acid was neutralised with equimolar sodium bicarbonate and sonicated for 5 min to form micelles. Indomethacin was purchased from Sigma (Dorset, UK). BWA4C was kindly donated by L. Garland, Wellcome Research Laboratories, Kent, UK. The fatty acid composition of the rat and mouse breeding diet and arachis oil was determined by gas-liquid chromatographic (GIC) analysis of the fatty acids as the methyl esters as previously described (Hudson et al., 1993) and is given in Table I In vivo cell cycle kinetics The protocol used to measure the kinetics of in vivo growth stimulation by LA was similar to that described previously (Gabor et al., 1985; Gabor & Abraham, 1986 (Figure 3a) , while AA only produced growth inhibition at concentrations greater than 33 ;M (Figure 3b ).
To investigate the potential role of metabolites of LA and AA in the growth-promoting effect, the action of the cyclooxygenase and lipoxygenase inhibitor indomethacin and the 5-lipoxygenase inhibitor BWA4C (Tateson et al., 1988) on PUFA-stimulated cell growth was determined. For the MAC26 cell line growth stimulation by either 10% fetal calf serum or 33 i1M AA in medium containing 1% fetal calf serum was inhibited by both agents in a dose-dependent manner at concentrations above 10 iLM. However, for BWA4C concentrations below 10 pM were synergistic with AA in stimulating growth of the MAC26 cell line (Figure 4) .
The IC5o values for indomethacin (32 ± 8 and 43 ± 15 ELM) and BWA4C (2 ± 1 and 10 ± 2 gM) were similar for stimulation by calf serum and AA, while growth stimulation by 18 gtM LA seemed much more resistant to inhibition by either agent (IC54 80± 21 and 22± 6) respectively). For the MAC13 cell line, growth stimulation by LA in medium containing 0.5% fetal calf serum was inhibited by both indomethacin and BWA4C. The IC50 values for growth * * -----s n * * ------* * ------ Indomethacin (5 mg kg-effectixelx abolished the growxth stimulation of the M.AC26 tumour bv LA in x-ii-o (Figure 6 (. The increase in tumour x-olume in indomethacin-treated mice was siginificantl1 belowx that found in non-stimulated controls S and 9 davs after the initiation of the experiment. The increase in tumour volume in animals receixing indomethacin xwithout LA did not differ from those not receiving indomethacin
Discussion
There are noxv considerable data to support a role for lipids in signal transduction pathx-ax.s Merrill t'l. l989(. Tumour growth in vivo has been suggested as being limited by the availability of substances relased from host fat stores during lipolysis and in particular to the PUFAs, LA and AA (Sauer & Dauchy, 1988) . While some in vitro studies suggest that LA and AA are directly cytotoxic to human cancer cells (Begin et al., 1986) , others (Rose & Connolly, 1990 ) suggest growth stimulation by LA when the serum concentration of the medium is reduced or eliminated.
In the present studies both LA and AA were found to stimulate the growth of two murine colon adenocarcinoma cell lines, MAC26 and MAC13, in serum-depleted medium in vitro. The fatty acids were complexed with equal weights of bovine serum albumin, neutralised with sodium bicarbonate and sonicated for 5 min before addition to cells. This concentration of albumin was used to overcome problems associated with growth stimulation by albumin alone at the low concentration of serum. This process circumvents solubility problems, although the fatty acid-albumin ratio is much higher than found in vivo. The optimal concentration of both LA and AA required for growth stimulation in vitro lay between 18 and 33 jM, and higher concentrations were growth inhibitory. Thus, these PUFAs appear to have a dual effect on tumour cell growth in vitro. The growth inhibition observed at higher concentrations is probably explained by the toxicity of free fatty acids (cell membrane modification and disruption, uncoupling of oxidative phosphorylation). of the caloric intake. This figure is close to the threshold level of PUFAs (4% of total energy) (Ip et al., 1985) required for mammary tumour promotion in vivo. Since this value is lower than the recommended (Report of the British Nutrition Foundation's Task Force, 1992) human intake (6%), human tumour growth may be already maxvimally stimulated by dietary consumption of LA.
The kinetics of growth stimulation of the MAC26 tumour by LA suggests that the increase in tumour volume results from an increase in the cell production rate. This conclusion differs from that of Gabor et al. (1985) , who supposed that stimulation of the growth of a mammary adenocarcinoma in mice by a diet containing 10% corn oil was the result of a reduction in the cell loss parameter. These results suggest that there may be more than one mechanism for stimulation of tumour growth by LA. Growth stimulation of the MAC26 tumour by LA in vivo was effectively abolished by indomethacin. This suggests the possible involvement of cyclo-oxygenase metabolites. However, since indomethacin is also capable of inhibiting the lipoxygenase pathway, the effect of other inhibitors must be evaluated before the precise metabolic pathway can be delineated. Another inhibitor of the cyclo-oxygenase pathway, piroxicam, has also shown inhibition of colon carcinogenesis (Reddy et al., 1987) , although again this is complicated by the fact that this is also an inhibitor of ornithine decarboxylase.
